Wir sind mit live! Mehr erfahren

Certara

CERT

Börsenwert 1,43 Mrd. $

9,37 USD

-0,29

3 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

9,20

-0,17

1,81 %

1 Tag

-3 %

5 Tage

2,74 %

1 Monat

15,25 %

3 Monate

28,71 %

6 Monate

52,11 %

Seit Jahresbeginn

7,21 %

1 Jahr

-25,99 %

5 Jahre

-74,4 %

10 Jahre

-75,39 %

Profil: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

Mitarbeiter: 1.576

Gesundheitswesen Gesundheitsinformationsdienste

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 0 %

Neutral 85,7 %

Negativ 14,3 %

Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript

Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript

Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

Certara Q2 Earnings Call Highlights

Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.

Certara Q2 Earnings Call Highlights

Zacks Investment Research

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara Reports Second Quarter 2026 Financial Results

Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.

Certara Reports Second Quarter 2026 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt